Genetics and Environment iNtersection In the ALS-FTD Spectrum: an Italian Twins Cohort studY With a Multi-Omics Approach
NCT06595212
Summary
The goal of this study is to learn from discordant twins affected by Amyotrophic Lateral Sclerosis and/or Frontotemporal Dementia the contribution of genetic background versus environmental exposure. The main questions it aims to answer is: * How far does the genetic background explain the onset of ALS/FTD in discordant twins? * Which environmental factors and events occurring in post-fetal life influence the onset or progression of this neurodegenerative condition? Participants with ALS and/or FTD with a monozygotic or dizygotic twin willing to contribute to this research will be followed up for two years by specialized Motor Neuron Disorders centers in Italy, donating biological specimen for -omic sciences analysis, and checking out if prodromal signs/symptoms of these two conditions will develop during time.
Eligibility
Inclusion Criteria: * Age \>18 yrs * Presence of MZ or DZ twins in the family both willing to participate in the study and able to provide informed consent * At least one twin is affected by ALS as defined by Gold Coast Criteria (Shefner et al., 2020) and/or by FTD as defined by Strong and colleagues (Strong et al., 2017) * Subjects able and willing to comply with study procedures as per protocol * Subjects able to understand, and capable of providing informed consent at screening visit before any protocol-specific procedures Exclusion Criteria: * Unwillingness to perform assessments as stated in the protocol at least during baseline visit for both twins * Unwillingness to donate biological samples collected at periphery (lumbar puncture excluded) for both twins * Women who are pregnant or breastfeeding
Conditions3
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06595212